Tate & Lyle Ventures is the corporate venture capital arm of Tate & Lyle PLC. See sector focus and contact routes.
Tate & Lyle Ventures is the corporate venture capital arm of Tate & Lyle PLC, a global leader in specialty food and beverage ingredients founded in 1903 and headquartered in London [1][2]. The firm invests in high-growth startups focused on food sciences and technologies, including nutrition, high-intensity sweeteners, salt replacers, alternative proteins, and diagnostic platforms for health management [1][4]. It targets both developed and emerging markets, focusing on expansion-stage companies and startups that align with Tate & Lyle’s strategy for next-generation food innovation [1][5]. The firm manages two funds: a £25 million fund launched in 2006 (now fully committed) and an active £30 million fund, with typical investments supporting 8–10 start-ups over an eight-year period [3][5]. While specific check sizes and lead/follow behavior are not publicly detailed, the firm has made 21 investments and achieved five exits, including Prolupin and CuraSen Therapeutics [3]. Notable portfolio companies include Prolupin, an alternative protein developer, and CuraSen Therapeutics, which received a Series B investment in 2022 [3]. The firm emphasizes strategic partnership alongside capital
StartupFundraising tracks this firm record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to comparable investors.
Investors like Tate & Lyle · Full investor directory · Investor access · Company funding database